CAPiTA
Related
Beyond the Scale: EASD 2026 and the Next Era of Cardiometabolic Trials
The question driving metabolic drug development is no longer how much weight or glucose a therapy can lower. It is how long the benefit lasts, what patients lose along the way, and which diseases downstream of obesity can be modified as a result. ...
Everyone Wants the Same Patient: The Recruitment Collision in Early-Stage Parkinson’s Trials
Symptomatic and disease-targeting studies may draw from overlapping early-stage populations, specialist sites, and referral networks. Sponsors that assess this competition before study launch will be better positioned to enroll efficiently and pro...
From Pipeline Progress to Precision Care: Five Takeaways from Two Leading MASH Conferences
Our team recently attended two leading forums focused on the future of MASH research and treatment: the 2026 Paris MASH Meeting and the 10th MASH Drug Development Summit in Boston. Together, the conferences brought perspectives from clinical pract...